Vanguard Group’s Lexeo Therapeutics LXEO Stock Holding History

Vanguard Group’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$38.7M	Buy	3,894,310 +1,668,020	+75%	+$15.2M	﹤0.01%	2306
2025 Q3	$14.8M	Buy	2,226,290 +223,424	+11%	+$1.08M	﹤0.01%	2774
2025 Q2	$8.05M	Buy	2,002,866 +903,581	+82%	+$2.97M	﹤0.01%	3022
2025 Q1	$3.81M	Sell	1,099,285 -19,594	-2%	-$86.8K	﹤0.01%	3272
2024 Q4	$7.36M	Buy	1,118,879 +254,168	+29%	+$2M	﹤0.01%	3103
2024 Q3	$7.82M	Buy	864,711 +234,792	+37%	+$2.8M	﹤0.01%	3077
2024 Q2	$10.1M	Buy	629,919 +148,164	+31%	+$2.15M	﹤0.01%	2912
2024 Q1	$7.55M	Buy	481,755 +65,573	+16%	+$1.03M	﹤0.01%	3115
2023 Q4	$5.59M	Buy	+416,182	New	+$5.17M	﹤0.01%	3244

Other funds holding LXEO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Group's LXEO Position: Q4 2025 in Review

Vanguard Group increased its Lexeo Therapeutics (LXEO) stake by 75% in Q4 2025, buying an estimated $15.2M and bringing the position to 3,894,310 shares worth $38.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2306.

Vanguard Group first reported a position in LXEO in Q4 2023 and has held it in 9 quarters since. 146 funds tracked by Wall St. Rank hold LXEO as of Q4 2025.

Vanguard Group held 3,894,310 shares of Lexeo Therapeutics worth $38.7M as of Q4 2025.
Vanguard Group bought 1,668,020 Lexeo Therapeutics shares in Q4 2025, an estimated $15.2M.
Lexeo Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2306 holding.
Vanguard Group first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 9 quarters since.
146 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.